Monopar Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Selling, General & Admin	3.23	2.95	2.63	2.44	2.36	1.56	1.17	0.91
Research & Development	5.6	7.59	6.49	4.07	1.97	1.77	0.94	0.28
Other Operating Expenses	0	0	0	0	0	0	14.5	0
Operating Expenses	8.83	10.54	9.13	6.51	4.32	3.33	16.6	1.19
Operating Income	-8.83	-10.54	-9.13	-6.51	-4.32	-3.33	-16.6	-1.19
Other Expense / Income	-0.43	-0.02	-0.02	-0.2	-0.1	-0.1	-0.05	-0.01
Pretax Income	-8.4	-10.52	-9.1	-6.3	-4.22	-3.23	-16.55	-1.19
Net Income	-8.4	-10.52	-9.1	-6.3	-4.22	-3.23	-16.55	-1.19
Shares Outstanding (Basic)	14	13	12	11	9	9	9	9
Shares Outstanding (Diluted)	14	13	12	11	9	9	9	-
Shares Change	8.69%	1.98%	13.81%	17.56%	0.32%	5.80%	-5.48%	-
EPS (Basic)	-0.61	-0.83	-0.73	-0.58	-0.45	-0.35	-1.89	-
EPS (Diluted)	-0.61	-0.83	-0.73	-0.58	-0.45	-0.35	-1.89	-
Free Cash Flow	-7.86	-7.23	-7.32	-4.66	-3.02	-2.68	-2.63	-1.19
Free Cash Flow Per Share	-0.57	-0.57	-0.59	-0.42	-0.32	-0.29	-0.30	-0.13
EBITDA	-8.4	-10.52	-9.1	-6.3	-4.22	-3.23	-16.55	-1.19
EBIT	-8.4	-10.52	-9.1	-6.3	-4.22	-3.23	-16.55	-1.19

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).